PMID- 36612039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Dec 21
TI  - Blinatumomab in Relapsed/Refractory Burkitt Lymphoma.
LID - 10.3390/cancers15010044 [doi]
LID - 44
AB  - In patients with relapsed/refractory Burkitt lymphoma (r/r BL), overall survival 
      (OS) is poor, and effective therapies and evidence for the best therapy are 
      lacking. The monoclonal antibody blinatumomab may represent a novel option. 
      However, only limited data on the use of blinatumomab in r/r BL are so far 
      available. This multi-center, retrospective case series investigated nine 
      patients with r/r BL treated with blinatumomab. The safety of blinatumomab was 
      assessed with respect to frequency and severity of adverse effects (AEs) 
      infections, cytokine release syndrome (CRS) and neurotoxicity. Progression-free 
      survival (PFS), OS and overall response rate (ORR) were analyzed to assess 
      efficacy. No AEs > grade 2 occurred, and AEs were generally treatable and fully 
      reversible. The best response to blinatumomab was complete remission in 3/9 
      patients and partial remission in 2/9, whilst 4/9 presented with progressive 
      disease. Median PFS and OS were 2 and 6 months, respectively, ranging from 5 days 
      to 32 months and 11 days to 32 months, respectively. Blinatumomab treatment was a 
      successful bridging treatment to stem cell transplantation in 3/9 patients. The 
      response to blinatumomab varied widely, and only one patient survived longer 
      term, but activity in patients with r/r BL was evident in some patients, with its 
      use being safe, warranting its prospective investigation.
FAU - Bohler, Jeanne
AU  - Bohler J
AD  - Department of Medical Oncology, University Hospital Inselspital and University of 
      Bern, 3010 Bern, Switzerland.
FAU - Bacher, Ulrike
AU  - Bacher U
AUID- ORCID: 0000-0001-8771-947X
AD  - Department of Hematology and Central Hematology Laboratory, University Hospital 
      Inselspital and University of Bern, 3010 Bern, Switzerland.
FAU - Banz, Yara
AU  - Banz Y
AD  - Institute of Pathology, University of Bern, 3008 Bern, Switzerland.
FAU - Stadelmann, Raphael
AU  - Stadelmann R
AD  - Division of Hematology, Department of Oncology, Lausanne University Hospital and 
      University of Lausanne, 1011 Lausanne, Switzerland.
FAU - Medinger, Michael
AU  - Medinger M
AUID- ORCID: 0000-0003-0427-7747
AD  - Department of Hematology, University Hospital, 4031 Basel, Switzerland.
FAU - Zander, Thilo
AU  - Zander T
AD  - Department of Oncology, Kantonsspital, 6000 Lucerne, Switzerland.
FAU - Pabst, Thomas
AU  - Pabst T
AUID- ORCID: 0000-0002-6055-5257
AD  - Department of Medical Oncology, University Hospital Inselspital and University of 
      Bern, 3010 Bern, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20221221
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9817963
OTO - NOTNLM
OT  - Burkitt lymphoma (BL)
OT  - adverse effects (AEs)
OT  - blinatumomab
OT  - cytokine release syndrome (CRS)
OT  - efficacy
OT  - infections
OT  - neurotoxicity
OT  - relapsed/refractory (r/r)
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/09 06:01
PMCR- 2022/12/21
CRDT- 2023/01/08 01:07
PHST- 2022/10/31 00:00 [received]
PHST- 2022/12/12 00:00 [revised]
PHST- 2022/12/16 00:00 [accepted]
PHST- 2023/01/08 01:07 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/09 06:01 [medline]
PHST- 2022/12/21 00:00 [pmc-release]
AID - cancers15010044 [pii]
AID - cancers-15-00044 [pii]
AID - 10.3390/cancers15010044 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 21;15(1):44. doi: 10.3390/cancers15010044.